Advertisement

Digestive Diseases and Sciences

, Volume 42, Issue 10, pp 2132–2137 | Cite as

Initial and Chronic Gastric Acid Inhibition by Lansoprazole and Omeprazole in Relation to Meal Administration

  • Robert-J.M. Brummer
  • Bertine J. Geerling
  • Reinhold W. Stockbrugger
Article

Abstract

In a placebo-controlled, double-blind, multiplecrossover study, the initial and chronic acid-inhibitoryeffect of lansoprazole 30 mg, orally administered halfan hour before breakfast or immediately after breakfast, and of omeprazole 20 mg,administered postprandially, respectively, wasinvestigated in 16 healthy volunteers, using ambulant24-hr intragastric pH monitoring. On the first day ofmedication, only preprandially administered lansoprazolereduced acid secretion significantly (median 24-hr pH3.0; P < 0.05). On day 15, the median 24-hrintragastric pH of lansoprazole preprandial (pH 4.1),lansoprazole postprandial (pH 4.3), and omeprazolepostprandial (pH 3.3), respectively, differedsignificantly (P < 0.05) from placebo (pH 1.2). It isconcluded that the interaction between food intake andlansoprazole administration only is important at the startof oral therapy. Lansoprazole taken before breakfast iseffective even on the initial day oftreatment.

LANSOPRAZOLE OMEPRAZOLE HR INTRAGASTRIC PH MONITORING ACID INHIBITION FOOD-DRUG INTERACTION BIOAVAILABILITY 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Burget DW, Chiverton SC, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99:345-351, 1990Google Scholar
  2. 2.
    Bell NVJ, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33:118-124, 1992Google Scholar
  3. 3.
    Hawkey CJ, Long RG, Bardhan KD, Wormsley KG, Cochran KM, Christian J, Moules IK: Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 34:1458-1462, 1993Google Scholar
  4. 4.
    Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, Sjöstedt S, Smith PM, Stig R, Wormsley KG, Langworthy H, Moules IK: Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 8:215-220, 1994Google Scholar
  5. 5.
    Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE: A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 9:25-31, 1995Google Scholar
  6. 6.
    Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP: Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acis secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 8:309-314, 1994Google Scholar
  7. 7.
    Verdu EF, Fraser R, Armstrong D, Blum AL: Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 29:1065-1069, 1994Google Scholar
  8. 8.
    Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI: Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Pharmacol 36:391-398, 1993Google Scholar
  9. 9.
    Andersson T, Andrén, Cederberg C, Heggelund A, Lundborg P, Röhss K: Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh day of treatment. Drug Invest 2:184-188, 1990Google Scholar
  10. 10.
    Howden CW, Meredith PA, Forrest JAH, Reid JL: Oral pharmacokinetics of omeprazole. Eur J Pharmacol 26:641-643, 1984Google Scholar
  11. 11.
    Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ, Smallwood RA, Louis WJ: Omeprazole: A study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 88:64-69, 1985Google Scholar
  12. 12.
    Watanabe K, Furuno K, Eto K, Oishi R, Gomita Y: First-pass metabolism of omeprazole in rats. J Pharmaceutical Sc 83:1131-1134, 1994Google Scholar
  13. 13.
    Larson C, Cavuto NJ, Flockhart DA, Weinberg RB: Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Dig Dis Sci 41:475-479, 1996Google Scholar
  14. 14.
    Bergstrand R, Grind M, Nyberg G, Olofsson B: Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 9:67-71, 1995Google Scholar
  15. 15.
    Delhotel-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B: The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet Special Issue No. III:315-320, 1991Google Scholar
  16. 16.
    Tateno M, Nakamura N: Phase I study of lansoprazole (AG-1749) antiulcer agent: Capsule form. Rinsho Iyaku 7:51-62, 1991Google Scholar
  17. 17.
    Moules I, Garrett A, Brocklebank D, Oliver S: Gastric acid inhibition by the proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 4:153-161, 1993Google Scholar
  18. 18.
    Bell NCV, Chiba N, Rinham GL, Hunt RH: Time to maximum effect of lansoprazole on gastric pH in male, normal volunteers. Gastroenterology 101:A345, 1992Google Scholar
  19. 19.
    Cederberg C, Röhss K, Lundborg P, Olbe L: Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 28:179-184, 1993Google Scholar
  20. 20.
    Fuder H, Ehrlich A, Wieckhorst G, Lücker PW, Cain CR: Pantoprazole once daily versus twice daily: A pH-metry study. Gut 39(suppl 3):A109, 1996Google Scholar
  21. 21.
    Delhotal-Landes B, Petite JP, Flouvat B: Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28:458-470, 1995Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Robert-J.M. Brummer
  • Bertine J. Geerling
  • Reinhold W. Stockbrugger

There are no affiliations available

Personalised recommendations